British pharma giant AstraZeneca‘s (NYSE: AZN) comeback story took a major blow this morning after the company reported that the all-important Mystic trial assessing Imfinzi (durvalumab) in combination with tremelimumab missed its primary endpoint of improving progression-free survival in non-small cell lung cancer (NSCLC) patients. Astra’s shares fell by a whopping 15.6% in pre-marketing trading on the back of this news, which is the steepest decline in the company’s history.
Image source: Getty Images.